Eklira Genuair Inhaler / Dry Powder
Aclidinium bromide
322mcg/Dose
AstraZeneca AB
| Pack size | 60 Dose Inhaler |
|---|---|
| Dispensing mode | POM |
| Source | SWEDEN |
| Agent | Modern Pharmaceutical Co. |
| Retail Price | 166.50 AED |
Indications
Eklira Genuair Inhaler / Dry Powder is used for:
Aclidinium bromide inhalation powder is indicated for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Aclidinium bromide :
Mechanism of Action
Aclidinium is a long-acting, competitive, and reversible anticholinergic drug that is specific for the acetylcholine muscarinic receptors. It binds to all 5 muscarinic receptor subtypes to a similar affinity. Aclidinium's effects on the airways are mediated through the M3 receptor at the smooth muscle to cause bronchodilation. Prevention of acetylcholine-induced bronchoconstriction effects was dose-dependent and lasted longer than 24 hours.
Note
Eklira Genuair 322mcg/Dose Inhaler / Dry Powder manufactured by AstraZeneca AB. Its generic name is Aclidinium bromide. Eklira Genuair is availble in United Arab Emirates.
Farmaco UAE drug index information on Eklira Genuair Inhaler / Dry Powder is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.